90.47
3.65 (4.20%)
Penutupan Terdahulu | 86.82 |
Buka | 90.02 |
Jumlah Dagangan | 167,082 |
Purata Dagangan (3B) | 838,223 |
Modal Pasaran | 21,748,355,072 |
Harga / Pendapatan (P/E Ke hadapan) | 7.04 |
Harga / Jualan (P/S) | 7.06 |
Harga / Buku (P/B) | 1.00 |
Julat 52 Minggu | |
Tarikh Pendapatan | 5 May 2025 |
Margin Keuntungan | -24.18% |
Margin Operasi (TTM) | 13.32% |
EPS Cair (TTM) | -3.02 |
Pertumbuhan Hasil Suku Tahunan (YOY) | -19.50% |
Pertumbuhan Pendapatan Suku Tahunan (YOY) | -43.30% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.31% |
Nisbah Semasa (MRQ) | 7.45 |
Aliran Tunai Operasi (OCF TTM) | 207.70 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 534.99 M |
Pulangan Atas Aset (ROA TTM) | -3.53% |
Pulangan Atas Ekuiti (ROE TTM) | -3.36% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Bercampur | Bercampur |
Biotechnology (Global) | Bercampur | Bercampur | |
Stok | BioNTech SE | Bercampur | Menaik |
AISkor Stockmoo
Konsensus Penganalisis | 4.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | 2.0 |
Purata Bergerak Teknikal | 2.5 |
Osilator Teknikal | -2.5 |
Purata | 1.50 |
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product. |
|
Sektor | Healthcare |
Industri | Biotechnology |
% Dimiliki oleh Orang Dalam | 63.23% |
% Dimiliki oleh Institusi | 21.87% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Altrinsic Global Advisors Llc | 31 Dec 2024 | 627,493 |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 171.44 (Canaccord Genuity, 89.50%) | Beli |
Median | 145.00 (60.27%) | |
Rendah | 139.00 (Morgan Stanley, 53.64%) | Beli |
Purata | 148.69 (64.35%) | |
Jumlah | 5 Beli | |
Harga Purata @ Panggilan | 96.59 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
HC Wainwright & Co. | 01 Apr 2025 | 145.00 (60.27%) | Beli | 90.29 |
Citigroup | 13 Mar 2025 | 145.00 (60.27%) | Beli | 97.47 |
BMO Capital | 11 Mar 2025 | 143.00 (58.06%) | Beli | 98.39 |
Canaccord Genuity | 11 Mar 2025 | 171.44 (89.50%) | Beli | 98.39 |
Morgan Stanley | 11 Mar 2025 | 139.00 (53.64%) | Beli | 98.39 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
10 Mar 2025 | Pengumuman | BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update |
10 Mar 2025 | Pengumuman | BioNTech Announces Fourth Quarter and Full Year 2024 Financial Results and Corporate Update |
24 Feb 2025 | Pengumuman | BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025 |
24 Feb 2025 | Pengumuman | BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025 |
04 Feb 2025 | CNBC | Vaccine stocks fall as Senate panel advances RFK Jr.'s nomination for HHS secretary |
03 Feb 2025 | Pengumuman | BioNTech Completes Acquisition of Biotheus |
03 Feb 2025 | Pengumuman | BioNTech Completes Acquisition of Biotheus |
14 Jan 2025 | Pengumuman | BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference |
14 Jan 2025 | Pengumuman | BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference |
Tarikh EX | Tarikh Pengumuman | Tarikh Pembayaran | Perincian |
---|---|---|---|
02 Jun 2022 | - | 17 Jun 2022 | 2.111 Tunai |
Hasil Dividen Tahunan
Tahun | Dividen Tahunan ($) | Kekerapan/Tahun | Hasil % |
---|---|---|---|
2022 | 2.11 | 1 | 1.41 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |